E. R. Squibb Sons, Inc.

Pfizer Corporation

Bristol-myers Squibb Compnay

Medarex Inc.

N.v. Organon

Oxford Biotherapeutics Ltd

Heidi N Leblanc

Mark Yamanaka

Alan J Korman

Mark J Selby

Kent B Thudium

Kyra D Zens

Haichun Huang

Kristopher Toy

Arvind Rajpal

Brigitte Devaux

Peter Brams

Ronald P Gladue

Barrett Richard Thiele

Rory Francis Finn

Yanli Wu

Wei Liao

Yi Wu

Jing Min

Timothy J Paradis

Timothy W Sproul

Edward L Halk

Jonathan Alexander Terrett

Andrea Van Elsas

Jennifer Marie Mataraza

Chin Pan

Chetana Rao-Naik

Tim Sproul

David J King

Alison Witte

David B Passmore

Richard Theolis

Dawn M Tanamachi

Li-Sheng Lu

Asna Masood

Sarah R Reed

Dapeng Yao

Bingliang Chen

Erika Meaddough

Ronald Paul Gladue

Timothy Joseph Paradis

Wei Laio

Sara R Dwiggins

David John King

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.

Fully human antibodies to BTLA

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.

Monoclonal antibodies against Glypican-3

Growing community of inventors

Mountain View, CA, United States of America

Heidi N Leblanc